This susceptibility has been successfully leveraged for the development of targeted and less-toxic therapeutic strategies for treatment of breast, ovarian and pancreatic cancers harbouring BRCA1 and/or BRCA2 mutations, notably poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors10, 11. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.